UK vape firm Plxsur sold for £76,500 after touting $1 billion revenue target

Jan.22
UK vape firm Plxsur sold for £76,500 after touting $1 billion revenue target
London-based vaping company Plxsur, which had claimed in fundraising materials it could reach $1 billion in annual revenue and capture about 10% of the global vaping market, has been sold out of administration for £76,500. Administrators said the figures were aspirational and depended on acquisitions that were never completed, as the company later ran out of cash and entered insolvency, with a shareholder ultimately buying the business.

Key points 

 

  • Plxsur was bought out of administration for £76,500 (about $97,000).
  • The company pitched a “roll-up and sell to Big Tobacco” strategy, but never exercised any of its 12 acquisition options.
  • In a March 2024 corporate presentation, Plxsur cited targets including ~10% global market share, $1 billion in revenue and over $200 million in earnings; administrators said the figures were aspirational and depended on acquisitions that did not happen.
  • Goldman Sachs worked on a sale but did not find a Big Tobacco buyer; Stifel later sought credit financing, also without success.
  • By late 2025, Plxsur had run short of cash, had no operating cash flow, and entered insolvency.

 

2Firsts, Jan. 22, 2026

 

According to Bloomberg News, UK vaping company Plxsur entered administration after failing to attract investment and running out of cash, before being bought out of the insolvency process for £76,500 (about $97,000), bringing its roll-up ambitions to an abrupt end.

 

Bloomberg cited documents from administrator KR8 Advisory Ltd. saying London-based Plxsur had signed 12 agreements that gave it the option to acquire vaping operations — including manufacturers in Latvia and the Czech Republic — but it ultimately did not complete any acquisitions.

 

Even so, Plxsur said in a March 2024 corporate presentation that it could secure about 10% of the global vaping market, lift annual revenue to $1 billion, and generate more than $200 million in earnings. KR8’s report said these figures were aspirational, reflecting the revenue scale Plxsur might have achieved if it had completed the acquisitions.

 

Bloomberg reported that Plxsur hired Goldman Sachs Group Inc. bankers to run a sale process, but failed to find a Big Tobacco buyer for the combined business. After that effort was paused, Plxsur selected Stifel Financial Corp. to seek credit investors willing to finance its acquisition strategy, but no deal materialised, according to people familiar with the matter.

 

Sources told Bloomberg that HPS Investment Partners came closest to providing a loan before walking away. A separate proposal later considered by investors led by New York-based private equity firm Cartesian Capital Group involved a roughly $90 million investment and a merger with a Nasdaq-listed SPAC, but that transaction also collapsed.

 

By late 2025, Plxsur’s cash position had deteriorated and, without operating cash flow or new capital injections in either equity or debt, the business fell into insolvency. KR8’s report said the buyer out of administration was James Cox, a Plxsur shareholder.

 

Bloomberg said a Goldman representative declined to comment, while Stifel, HPS and Cartesian did not respond to requests for comment.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | China’s Tobacco Tax Debate Shifts Toward Tax Design as Policy Trade-offs Come Into Focus
Special Report | China’s Tobacco Tax Debate Shifts Toward Tax Design as Policy Trade-offs Come Into Focus
China’s tobacco tax debate is moving from whether to raise prices to how the tax system should be designed. At a Beijing forum on World No Tobacco Day, experts discussed higher specific excise taxes, minimum tax burdens and dynamic adjustments linked to income and inflation. The issue also connects to China’s broader consumption tax reform, health financing and chronic disease costs. Public reports did not mention e-cigarettes, heated tobacco, nicotine pouches or other new nicotine products.
Jun.11
Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control
Nature Health Comment Urges Wider Role for Smoke-Free Nicotine Products in Tobacco Control
Ahead of World No Tobacco Day, a Nature Health Comment by Robert Beaglehole, Ruth Bonita and Tikki Pang argues that regulated smoke-free nicotine products could help accelerate the global decline in smoking. The authors propose a “smoke-free 2040” goal and call for risk-proportionate regulation distinguishing cigarettes from lower-risk nicotine alternatives.
News
May.20
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
Philip Morris Japan announced on April 23 at a product briefing that ZYN by IQOS, an oral tobacco pouch previously launched in selected areas, will expand sales in Tokyo. The company said the product will be released progressively from May 11 through IQOS shops, Lawson and other outlets in the city. The launch will include four flavors, each offered in Low and Medium intensity levels, for a total of eight products.
Apr.27 by 2FIRSTS.ai
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japan Tobacco Q1 2026 Financial Results: Revenue at $5.914 Billion,RRP Revenue Up 63.8% YoY
Japanese Tobacco (JT) reports Q1 2026 revenue of 924 billion yen, a 15.2% increase; operating profit rises 24.7%.
May.08 by 2FIRSTS.ai
Canada Faces Growing Debate as Youth Nicotine Pouch Use Reaches 34.8%
Canada Faces Growing Debate as Youth Nicotine Pouch Use Reaches 34.8%
New Canadian research shows that 34.8% of people aged 17 to 27 have tried nicotine pouches, up more than fourfold from 7.6% in 2022. The findings come as Conservative politicians, Alberta’s government and the tobacco industry push Ottawa to relax current restrictions on pouch sales.
Jun.12
Imperial Brands Launches 2ml+10ml blu MAX 6000 Vape System
Imperial Brands Launches 2ml+10ml blu MAX 6000 Vape System
mperial Brands has launched blu MAX 6000 in the UK, positioning the product as a higher-puff vape kit with longer-lasting use and replaceable pod+refill options. The device uses a 2ml+10ml click-on box format, with starter kits priced at £10.99 (approximately $14) and replacement pod+refill packs priced at £7.99 (approximately $10).
Market
May.19